7,8-dihydro-[2]naphthylamine | 103205-06-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7,8-dihydro-[2]naphthylamine
• 英文别名: 7,8-Dihydronaphthalen-2-amine
• CAS: 103205-06-7
• 化学式: C₁₀H₁₁N
• mdl: MFCD19210500
• 分子量: 145.204
• InChiKey: ODNXACLAJBPGQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  6-氨基-1,2,3,4-四氢-1-萘甲酸 在 水 、 silver(l) oxide 作用下， 生成 7,8-dihydro-[2]naphthylamine
  参考文献：
  名称：

  Umwandlungsprodukte des Dibrom-tetrahydronaphthoes�ureesters

  摘要：

  DOI：

  10.1007/bf00898767

文献信息

• [EN] NOVEL ULK1 INHIBITORS AND METHODS USING SAME<br/>[FR] NOUVEAUX INHIBITEURS D'ULK 1 ET LEURS MÉTHODES D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2016033100A1

  公开（公告）日：2016-03-03

  In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

  在某些方面，该发明提供了一种治疗受试者疾病或病况的方法，该方法包括向需要的受试者联合给予至少一种ULK1抑制嘧啶的治疗有效量，以及mTOR抑制剂的治疗有效量。
• FUSED PYRAZOLE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY
  申请人：The University of Tokyo

  公开号：EP3112369A1

  公开（公告）日：2017-01-04

  The present invention provides a compound of formula (I), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.

  本发明提供了一种式(I)的化合物，其中R1、R2、R3、R4a、R4b、R5a和R5b如描述中所定义，具有自体脂肪酶抑制活性，包括该化合物作为活性成分的药物组合物，以及一种预防或治疗涉及自体脂肪酶的疾病的方法，其特征在于给予该化合物。
• [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS)
  申请人：Samsung Display Co., Ltd.

  公开号：EP3301097A2

  公开（公告）日：2018-04-04

  The present invention relates to benzo[4',5']thieno[3',2':4,5]imidazo[1,2-a]pyridine derivatives and related compounds for use in organic light emitting devices (OLEDs). The OLED includes at two electrodes and an organic layer disposed between the electrodes including a compound of the present invention. The compounds of the present invention are represented by Formula 1: in Formula 1, A11 is a C1-C60 heterocyclic group, A12 is a C5-C60 carbocyclic group or a C1-C60 heterocyclic group, X11 is O or S, X12 is C, X13 is selected from N, C, and C(R13), X14 is selected from N, C, and C(R14), and X13 and X14 are linked via a single bond or a double bond.

  本发明涉及用于有机发光器件（OLED）的苯并[4',5']噻吩并[3',2':4,5]咪唑并[1,2-a]吡啶衍生物及相关化合物。 OLED 包括两个电极和置于电极之间的有机层，有机层中包括本发明的化合物。 本发明的化合物由式 1 表示： 式 1 中，A11 是 C1-C60 杂环基团，A12 是 C5-C60 碳环基团或 C1-C60 杂环基团，X11 是 O 或 S，X12 是 C、 X13 选自 N、C 和 C(R13)、 X14 选自 N、C 和 C(R14)，且 X13 和 X14 通过单键或双键相连。
• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING SAME, AND DIAGNOSTIC COMPOSITION INCLUDING SAME
  申请人：Samsung Electronics Co., Ltd.

  公开号：EP3772517A1

  公开（公告）日：2021-02-10

  An organometallic compound represented by Formula 1, wherein M1 is beryllium, magnesium, aluminum, calcium, titanium, manganese, cobalt, copper, zinc, gallium, germanium, zirconium, ruthenium, rhodium, palladium, silver, rhenium, platinum, or gold; A1 to A3 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group; A4 is a 5-membered heterocyclic group; A5 is a C7-C30 carbocyclic group of at least two rings comprising a 6-membered carbocyclic group, or A5 is a C1-C30 heterocyclic group of at least two rings comprising a 6-membered carbocyclic group or a 6-membered heterocyclic group; X10, X20, X30, and X40 to X44 are each independently C or N; T1 to T3 are each independently a single bond, *-N[(L1)a1-(R1)b1]-*', *-B(R1)-*', *-P(R1)-*', *-C(R1)(R2)-*', *-Si(R1)(R2)-*', *-Ge(R1)(R2)-*', *-S-*', *-Se-*', *-O-*', *-C(=O)-*', *-S(=O)-*', *-S(=O)2-*', *-C(R1)=C(R2)-*', *-C(=S)-*', or *-C≡C-*'; and wherein the other substituents may be understood by referring to the detailed description.

  一种由式1表示的有机金属化合物，其中M1是铍、镁、铝、钙、钛、锰、钴、铜、锌、镓、锗、锆、钌、铑、钯、银、铼、铂或金；A1至A3各自独立地是C5-C30碳环基团或C1-C30杂环基团；A4 是 5 元杂环基团； A5 是至少由两个环组成的 C7-C30 碳环基团，其中包括一个 6 元碳环基团，或 A5 是至少由两个环组成的 C1-C30 杂环基团，其中包括一个 6 元碳环基团或一个 6 元杂环基团；X10、X20、X30 和 X40 至 X44 各自独立地为 C 或 N；T1 至 T3 各自独立地为单键、*-N[(L1)a1-(R1)b1]-*'、*-B(R1)-*'、*-P(R1)-*'、*-C(R1)(R2)-*'、*-Si(R1)(R2)-*'、*-Ge(R1)(R2)-*'、*-S-*'、*-Se-*'、*-O-*'、*-C(=O)-*'、*-S(=O)-*'、*-S(=O)2-*'、*-C(R1)=C(R2)-*'、*-C(=S)-*'或*-C≡C-*'；其中其他取代基可参阅详细说明。
• alpha-AND gamma-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：The Research Foundation Of State University Of New York

  公开号：EP2874987B1

  公开（公告）日：2020-03-25